The Novo and Novartis-backed company, which is developing drugs to make radiotherapy less harmful, is set to raise between $70m and $80m.

Galera Therapeutics, a US-based radiotherapy medicine developer backed by pharmaceutical firms Novo and Novartis, set the terms yesterday for an initial public offering that will raise $80m at the top of its range. The offering is set to consist of 5 million shares issued on the Nasdaq Global Market priced between $14 and $16 each…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.